seronegative – Communicable Diseases Research

Variation in SARS-CoV-2 seroprevalence in children in the region of Asturias, Northern Spain

Article

Published on 2022-12-012022-11-15
Journal: World Journal of Pediatrics
[Category] COVID19(2023년), SARS, 진단,

Persistence of SARS-CoV-2 neutralizing antibodies longer than 13 months in naturally infected, captive white-tailed deer ( Odocoileus virginianus), Texas

Article

Published on 2022-12-012022-11-15
Journal: Emerging Microbes & Infections
[Category] COVID19(2023년), SARS, 진단, 치료기술,

Antibody response to SARS-CoV-2 vaccines among hospitalized patients in China: a case-control study

Article

Published on 2022-11-302022-11-15
Journal: Human vaccines & immunotherapeutics
[Category] COVID19(2023년), SARS, 진단,

Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection

Article

Published on 2022-11-012022-11-15
Journal: The Journal of Infectious Diseases
[Category] SARS, 바이오마커, 치료기술,

Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients

Article

Published on 2022-11-012022-11-15
Journal: Clinical gastroenterology and hepatology : the off
[Category] COVID19(2023년), SARS, 진단, 치료기술,

[키워드] acute respiratory syndrome anti-S anti-SARS-CoV-2 antibody Antibody Response Antibody titer cellular Cellular immune response coronavirus COVID-19 defined domain dose filtration first vaccination HCs healthy control humoral immune response Immunosuppression increase increase in investigated liver liver transplant liver transplant recipients LTR LTRs Lymphocyte count mRNA mRNA-based non-responders Odds ratio Patient Prospective Study RBD recipient responders response risk factor SARS-CoV-2 SARS-CoV-2 vaccination second vaccination Seroconversion seronegative seropositive spike-specific T-cell response T cells the median Third and Fourth SARS-CoV-2 Vaccination. Transplant vaccination Vaccinations
[DOI] 10.1016/j.cgh.2022.06.028 PMC 바로가기

Observational Study of Receptor Binding Domain Spike Antibody Responses to 3 SARS-CoV-2 Vaccinations in Noninfected Subjects: Parallel Neutralizing Antibody and Cardiac Troponin I and T Observations

Article

Published on 2022-10-292022-11-15
Journal: The journal of applied laboratory medicine
[Category] COVID19(2023년), SARS, 진단,

SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants

Article

Published on 2022-10-262022-11-15
Journal: mBio
[Category] COVID19(2023년), SARS, 변종, 진단, 치료기술,

[키워드] acute respiratory syndrome advanced age analyzed antibodies antibody antibody durability Antibody titer circulation Cohort collected convalescent coronavirus coronavirus disease COVID-19 decrease detectable determine Effectiveness Enrollment exceptional female Health care worker highlight immune responses Increases Infection initial limit Longevity median modeling mounted new SARS-CoV-2 occurred Pandemics participant Participants protection public health crisis Rapid Reinfection risk SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 variant seronegative seropositive seropositive participant severe COVID-19 Sex spike-binding antibodies. stability Steady state vaccination variants of concern viruses
[DOI] 10.1128/mbio.01784-22 PMC 바로가기

Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination

Article

Published on 2022-10-062022-11-15
Journal: Frontiers in Immunology
[Category] COVID19(2023년), SARS, 진단,

[키워드] acute respiratory syndrome analyzed antibody CD4 CD4+ CD4+ T cells CD8 CD8+ CD8+ T cells Cellular immune response competent coronavirus COVID-19 COVID-19 vaccination develop dose elicited ELISPOT exhibited had no healthy individuals humoral ICU immune protection immune response individual individuals information intensive care intensive care unit workers lack maintain mRNA mRNA COVID-19 vaccines mRNA vaccine neutralizing antibody proportion Protein protein S reactive receiving reduction in SARS-CoV-2 SARS-CoV-2-specific T cell Seroconversion seronegative Specific T-cell response susceptibility T cell T cell response T cells T lymphocyte T-cell the S protein the SARS-CoV-2 the spike protein vaccination vaccination. viral infection Viral protein
[DOI] 10.3389/fimmu.2022.942192 PMC 바로가기

Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults

Article

Published on 2022-10-042022-11-16
Journal: Frontiers in Immunology
[Category] COVID19(2023년), SARS, 변종,

[키워드] Activation Adaptive immune response antibodies antibody BCG BCG vaccination benefit booster breadth CD4+ CD8+ T-cell changes changes in chromatin Combination COVID-19 vaccines Delta Effect effector memory eight elevated ENhance Epigenetic Evidence expressing greater Heterologous highlighting IL-1β IL-2 immune response Immunity in-depth analysis India marker memory T-cell response mutant NAb Neutralizing provide revaccination SARS-CoV-2 seronegative significantly higher subset T cell T-cell Response tested TNF-α TNF-α expression trained immunity. Tuberculosis vaccination Vaccine vaccine-induced immune response
[DOI] 10.3389/fimmu.2022.985938 PMC 바로가기

Differential vaccine-induced kinetics of humoral and cellular immune responses in SARS-CoV-2 naive and convalescent health care workers

Article

Published on 2022-10-032022-11-15
Journal: Pathogens and disease
[Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] assays B-cell baseline booster booster vaccines cellular Cellular immune response convalescent convalescent individual Coronavirus-2 determine ELISA ELISPOT ELISpot IFN-γ release assay first dose Health care worker health care workers hospital humoral humoral immune responses Humoral immunity IFN-γ IgG level IgG responses immune individual individuals interferon-γ janssen mounted mRNA mRNA vaccine natural immunity Netherlands occurred offer pandemic Pfizer postvaccination receiving recipient responses SARS-CoV-2 serological seronegative seropositive severe disease spike-specific cellular immunity Support T-cell T-cell Response vaccination Vaccine variants of concern vector vaccine. Virus neutralization VNT waned
[DOI] 10.1093/femspd/ftac035 PMC 바로가기